Previous 10 | Next 10 |
2023-04-27 12:24:19 ET Gainers: TOP Financial Group Limited ( TOP ) +186% . Evelo Biosciences ( EVLO ) +184% . ContraFect Corporation ( CFRX ) +68% . U Power Limited Ordinary Shares ( UCAR ) +40% . Atomera Incorporated ( ATOM ) +33...
2023-04-27 10:01:57 ET Gainers: ContraFect ( CFRX ) +112% . Accuray ( ARAY ) +14% . Mainz Biomed ( MYNZ ) +15% . Mangoceuticals ( MGRX ) +14% . Immix Biopharma ( IMMX ) +9% . Losers: Baudax Bio ( BXRX ) -52% ....
2023-04-27 09:38:46 ET Immix Biopharma's ( NASDAQ: IMMX ) subsidiary Nexcella released positive results from its ongoing Phase 1b/2 NEXICART-1 study on NXC-201, its autologous BCMA-targeted CAR-T cell therapy. to treat relapsed or refractory ( AL ) amyloidosis a...
Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its ongoing phase 1b/2a NEXICART-1 clinical trial (NCT04720313) who were not exposed to prior BCMA-targeted t...
LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at...
LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that an editorial written by Maria Sjöstrand and Michel Sadelain ...
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematolo...
LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysr...
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysr...
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis Nexcella on track to present 50-patient cohort multiple myeloma data later this year at ...
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for: EU protocol assistance, marketing authorization applications, inspections bef...